Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Clinical trial NCT04160052 · TERMINATED

Trial details

NCT number: NCT04160052
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Chronic Myelomonocytic Leukemia Myelodysplastic Syndrome Recurrent Myelodysplastic Syndrome Refractory Myelodysplastic Syndrome Therapy-Related Myelodysplastic Syndrome

Start date: 2019-10-01
Primary completion: 2026-02-03
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.